Company Overview
| Stock Name | 創美藥業股份有限公司 |
|---|---|
| Stock Code | 02289 |
| Company Full Name | 創美藥業股份有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事分銷藥品。 |
| Listing Date | 2015-12-14 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣東省汕頭市龍湖區嵩山北路235號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.chmyy.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 8.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 10.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 72,240,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 8.0 |
|---|---|
| First Day Open | HK$ 7.7 |
| First Day Change | -6.98% |
| First Day Volume | 8018500.0 |
| First Day Turnover | 64439800.0 |
Use of Proceeds
| Use of Proceeds | 1、約64.8百萬港元（約35%）將用于增強、擴展及整合我們現存的分銷網絡及能力； 2、約18.5百萬港元（約10%）將用于改良及推廣我們的B2B電子商務平臺； 3、約55.6百萬港元（約30%）將用于償還銀行借款； 4、約27.8百萬港元（約15%）將用于收購華南地區的醫藥分銷業務； 5、約18.5百萬港元（約10%）用于營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
国泰君安融资有限公司 CE AGS488
Overall Coordinators (1)
国泰君安证券（香港）有限公司 CE ABY236
Joint Bookrunners (1)
国泰君安证券（香港）有限公司 CE ABY236
Joint Lead Managers (3)
国泰君安证券（香港）有限公司 CE ABY236
EVER-LONG SECURITIES COMPANY LIMITED CE ACM423
LUK FOOK SECURITIES (HK) LIMITED CE ACU547
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 广药白云山香港有限公司 | 67,995,900 HKD | — | 7.30% | — | 6 months | 2016-06-14 |
| 2 | 香雪集团(香港)有限公司 | 29,996,800 HKD | — | 3.20% | — | 6 months | 2016-06-14 |
Directors & Management
| Chairman | 嚴京斌 |
|---|---|
| Company Secretary | 姚潔晞 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 姚創龍(40.97%);江西江中醫藥商業運營有限責任公司(26.90%) |
|---|
